NE BUSINESS BUREAU
AHMEDABAD, FEB 2
Lincoln Pharmaceuticals Limited, on Tuesday, has reported net profit of Rs 13.37 crore for the Q3 FY21 ended December 2020 as against net profit of Rs 10.18 crore in the corresponding period last year, a growth of 31.35%, a release said.
Net revenue for the Q3 FY21 was reported at Rs 113.26 crore, higher by 15.56% over previous fiscal’s same period net revenue of Rs. 98.01 crore. The company reported an EBITDA of Rs. 19.94 crore in Q3FY21, a rise of 43.25% as compared to Rs 13.92 crore in the corresponding period last year, the release added.
EPS for Q3FY21 was at Rs. 6.68 per share for as compared to Rs. 5.09 in the corresponding period last year.
Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “On back of strong domestic and international business, company posted 15.56 % sales growth, 4.00 % rise in exports and 31.35 % rise in the PAT for the quarter ended Q3FY21. Exports sales in nine months ended December 2020 was reported at Rs. 212.47 crore, growth of 17.56 % Y-o-Y. Geographical and product expansion coupled with operational efficiency contributing to the growth. The company is in the process of expanding its presence in Africa, South East Asian countries and exploring entry into the EU. Expanding the product basket, the company will be introducing 6-7 new products in the domestic markets and expects 20-25 new dossiers approval for the exports market.”
Performance for nine months ended December 2020
As a result of expansion in geographical reach in domestic markets, relentless focus on exports, and sustained marketing, the Net sales for the nine months ended December 2020 was reported at Rs.339.77 crore, higher by 10.44% over previous fiscal’s same period net sales of Rs. 307.65 crore. The company reported a net profit of Rs. 48.56 crore for the nine months ended December 2020 as against a net profit of Rs. 40.33 crore in the corresponding period last year, a growth of 20.74 %.
EPS for the 9MFY21 was reported at Rs. 24.28 per share. Exports for the 9MFY21 stood at Rs. 212.47 crore, up 17.56 % as against exports of Rs. 180.74 crore in 9MFY20.
To complement the company’s strong presence in the acute segment, the company is also building a portfolio in the lifestyle and chronic segment especially dermatology, gastro, and pain management and plans to introduce them in the EU markets. The company has received EU approval and plans to enter the region soon. Company currently exports to 60 plus countries and plans to expand to 90 plus countries in the next 1-2 years.
Financial Highlights (Standalone)
(Amount in Cr except EPS)
| Particulars | Q3 FY21 | Q3 FY20 | Y-O-Y | 9M FY21 | 9M FY20 | Y-O-Y |
| Net Revenue | 113.26 | 98.01 | 15.56% | 339.77 | 307.65 | 10.44% |
| EBITDA | 19.94 | 13.92 | 43.25% | 71.37 | 58.45 | 22.12% |
| Profit before Tax | 18.16 | 12.05 | 50.71% | 66.22 | 52.66 | 25.74% |
| Net Profit | 13.37 | 10.18 | 31.35% | 48.56 | 40.33 | 20.74% |
| E.P.S (Rs.) | 6.68 | 5.09 | 31.35% | 24.28 | 20.17 | 0.40% |
